Posted inInfectious Diseases news Respiratory
Three-Season Protection Against RSV in Older Adults: Insights from the AReSVi-006 Phase 3 Trial of the AS01E-Adjuvanted RSVPreF3 OA Vaccine
The AS01E-adjuvanted RSVPreF3 OA vaccine demonstrates robust efficacy against RSV-related lower respiratory tract disease over three seasons in adults aged 60+, with a favorable safety profile and promising immunogenicity findings.